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ABSTRACT 
INRODUCTION 
Hypertension is a major non-communicable disease which has major 
impact on morbity and mortality. Early detection of end organ damage may 
reduce the morbidity substantially 
 
AIM OF THE STUDY 
To study the prevalence of echocardiographic changes in hypertensive 
patients and to investigate correlation of echocardiographic changes with age, 
sex, duration and control of hypertension, tobacco use and body mass index. 
 
MATERIALS AND METHODS 
Patients with hypertension were recruited from hypertension clinic. A 
total of 100 patients who met inclusion and exclusion criteria were inducted into 
the study. Echocardiographic examination was performed to assess cardiac 
structural changes and cardiac function. The results were analyzed statistically 
 
RESULTS AND OBSERVATIONS 
In our study population, 64% had echocardiographic abnormality of left 
ventricle, either abnormal LV mass or LV Diastolic dysfunction out of which 
27% had both. 50% of the sample group had LV Diastolic dysfunction while 
41% had abnormal LV mass.  Overall 63% of those with abnormal LV mass 
were females. Even when the duration of hypertension is less than 5 years, 37% 
hypertensives had abnormal LV mass. 90% of those who had abnormal LV 
mass were tobacco users. Among obese hypertensives, 45% had abnormal LV 
mass and 57% had LV diastolic dysfunction. It is most important to note that 
74% of patients has inadequate control of BP (SBP>140 mmHg and/or DBP > 
90mmHg as per JNC7 guidelines) 
 
CONCLUSION 
In this study, half of asymptomatic hypertensives had evidence of LV diastolic 
dysfunction and even a short duration of hypertension results in abnormal LV 
mass and three-fourths of hypertensives have inadequate control of BP and two 
thirds of hypertensives were obese. This emphasizes importance of need for life 
style modifications and earlier achievement of target BP and implies the 
importance of screening of asymptomatic hypertensives for LV diastolic 
dysfunction. 
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INTRODUCTION
1. INTRODUCTION 
 
 
Systemic hypertension is a most common risk factor for ischaemic heart 
disease, peripheral vascular disease, aortic dissection, stroke, particularly heart 
failure, atrial fibrillation and also easily identified and reversible. Hypertension 
is a major global health problem affecting the public and a major cause of death 
globally. Since it is of asymptomatic nature, diagnosis is often delayed. 
To treat systemic hypertension effectively, continued and frequent 
follow-up is necessary which is not that common among men and low income 
groups. Most of the time, a single disease causing mechanism could not be 
identified and treatment is empiric. Insufficient time for education, Medication 
burden, drug costs, and side effects of medication leads to non-adherence. 
Physicians also often hesitate to start and intensify anti-hypertensive 
medication.  
Due to above mentioned reasons, Blood Pressure (BP) is controlled to a 
value less than 140/90 mm Hg in not more than one third of hypertensives, even 
in developed countries where most advance health care systems are available. 
Even when BP meets current standards, less than one in three are protected from 
complications. There is a probability of 90% chance of development of 
hypertension in a middle aged or elderly individual in their life time. Hence, 
assessment of risk of cardiovascular disease should be included in the 
evaluation of both individuals at risk of developing systemic hypertension and 
hypertensive patients.  
  
 
 
 
 
AIMS AND OBJECTIVES 
2. AIM OF STUDY 
 To study the prevalence of echocardiographic changes associated with 
systemic hypertension among hypertensive patients attending 
hypertension clinic at Govt. Royapettah hospital, Chennai 
 
 To correlate the echocardiographic changes observed with age, sex, 
duration of hypertension, control of hypertension, smoking, BMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
3. REVIEW OF LITERATURE 
 
Hypertension is a leading cause of global disease burden and an 
increasingly important public health problem. In the year 2001, approximately 
13–15% of the total deaths and 92 million DALY worldwide were attributable 
to high blood pressure. The risk of cardiovascular disease is doubled with 
hypertension along with ischemic and hemorrhagic stroke, peripheral arterial 
disease and chronic kidney disease. It has been found a large percentage of 
hypertensive population were either inadequately treated or untreated. 
Observational studies involving greater than 1 million individuals have shown 
that there is a linear progression in mortality from CAD and stroke from BP 
levels as low as SBP 115 mmHg and DBP 75 mmHg upward.[63]  As per 
Framingham Heart Study , there is a two fold increase of cardiovascular disease 
risk (relative risk ) for BP values between 130–139/85–89 mmHg.[64]  
3.1 EPIDEMIOLOGY 
Affecting 1 billion people worldwide, hypertension is one of the 
common, easily identifiable conditions which affects about one billion people 
all over the world and is also reversible with proper follow-up and treatment. 
Hypertension mat lead to stroke, heart failure, myocardial infarction, 
arrhythmias, peripheral vascular disease and aortic dissection. The global 
burden of hypertension is rising and projected to affect 1.5 billion persons—one 
third of the world's population—by the year 2025 due to aging population and 
increasing incidence of obesity.Currently, high blood pressure (BP) causes 
about 54% of stroke and 47% of ischemic heart disease worldwide.[1] 
Half of this disease burden is in people with hypertension; the other half 
is in people with lesser degrees of high BP (prehypertension). Thus, high BP is 
the leading cause of mortality globally and  leading public health problem in the 
world. 
The asymptomatic nature of the condition delays diagnosis. Effective 
treatment requires continuity of care by a knowledgeable physician and frequent 
medical checkups, which are less common in men and low-income minorities.[2] 
Even among patients whose hypertension control meets current standards, 
fewer than one in three is protected from end organ damage like heart failure, 
myocardial infarction or stoke.  
Blood pressure levels, the rate of age-related increases in blood pressure, 
and the prevalence of hypertension vary among populations.  Hypertension is 
not prevalent in a small number of individuals living in primitive, culturally 
isolated societies. In industrialized societies, blood pressure consistently 
increases in the first 10 -20 years of life. In younger age, blood pressure is 
associated with growth and maturation. Blood pressure "tracks" over time in 
children and between adolescence and young adulthood. In the United States, 
blood pressure is higher in men than in women in early adulthood. Among older 
individuals, women had steeper increase in age-related rate of rise of blood 
pressure. Consequently, among individuals age 60 and older, systolic blood 
pressures of women are higher than those of men. Diastolic blood pressure 
increases progressively until ~55 years among adults, after which it tends to 
decrease. The consequence is a widening of pulse pressure (the difference 
between systolic and diastolic blood pressure) beyond age 60. There ia a 90% 
probability of developing systemic hypertension in the life time of a middle-
aged or elderly person.  
The incidence of hypertension in increasing with age there is a 65.4% 
prevalence among persons aged > 60 years. Recent evidence suggests that the 
prevalence of hypertension may be increasing, possibly as a consequence of 
increasing obesity. 
Racial and regional variations in blood pressure prevalence may be 
contributed by b genetic and environmental factors. Weight gain and obesity are 
found to be strong, independent risk factors in hypertension. Sedentary life 
style, alcoholism, work related stress also may contribute to hypertension. 
Incidence of hypertension is 3.8 times more frequent in persons with positive 
family history of systemic hypertension. 
As per 2010 Non-communicable disease report for india published by 
WHO 32.5% of Indians had raised blood pressure of prevalence among males 
(33.2% ) and females (31.7%) was almost equal.[3] 
3.2 DEFINING HYPERTENSION 
Clinically, hypertension may be defined as that level of blood pressure at 
which the institution of therapy reduces blood pressure–related morbidity and 
mortality. Current clinical criteria for defining hypertension generally are based 
on the average of two or more seated blood pressure readings during each of 
two or more outpatient visits.  
JNC 7 recommends Blood pressure criteria for defining hypertension was 
recommended by JNC7[4] . Patients were classified as having normal blood 
pressure, prehypertension, hypertension (stages I and II). The JNC 7 
classification does not take in to account the target organ damage or presence or 
absence of risk factors in making recommendations for treatment, if both or 
either be present. As per JNC7 recommendation all persons with stage 1 and 
stage 2 systemic hypertension should be treated. Blood pressure <140/90 mmHg 
should be taken as the goal for persons with systemic hypertension and no other 
compelling indications. Compelling indications involve high-risk conditions 
that can be direct sequelae of hypertension (HF, IHD, chronic kidney disease, 
recurrent stroke) or commonly associated with hypertension (diabetes, high 
coronary disease risk). Therapeutic decisions in such individuals should be 
directed at both the compelling indication and BP lowering. The goal for 
persons having no compelling indications and prehypertension is to control BP 
to normal blood pressure levels with lifestyle modifications and prevent the 
progressive rise in BP. 
 
Fig 3.2.1 BLOOD PRESSURE IN ADULTS (AS PER JNC7 
GUIDELINE)[4] 
Clinic measured blood pressure levels are higher than Home measured 
blood pressure and average 24-h ambulatory measured blood pressure 
measurements are generally lower than clinic blood pressures. Increasing 
evidence suggests that home blood pressures, including 24-h blood pressure 
recordings, more reliably predict target organ damage than do office blood 
pressures. Blood pressure was found to be high in early morning of the, soon 
after waking. Nighttime measured blood pressures aer 10–20% lower than blood 
pressures measured during day time, and an attenuated nighttime blood pressure 
"dip" is associated with increased cardiovascular disease risk. Average awake 
measured BP 135/85 mmHg and asleep measured blood pressure 120/75 
mmHg approximate clinic measured blood pressure of 140/90 mmHg. 
Approximately 15–20% of patients with stage 1 hypertension based on 
office blood pressures have average ambulatory readings <135/85 mmHg. This 
phenomenon, so-called white coat hypertension, also may be associated with an 
increased risk of end organ damage although to a lesser extent than in 
individuals with elevated office and ambulatory readings and is also associated 
with increased chance of sustained systemic hypertension. 
The minimal laboratory testing required for the initial evaluation of 
hypertension includes determination of blood electrolyte values, fasting glucose 
concentration, and serum creatinine level, glomerular filtration rate, fasting lipid 
panel; hematocrit; spot urinalysis, including urine albumin-to-creatinine ratio; 
and resting 12-lead electrocardiogram. 
3.3 CAUSES OF HYPERTENSION 
Approximately 80–95% of hypertensive patients are diagnosed as having 
“primary” hypertension (also referred to as essential or idiopathic hypertension). 
In the rest 20% hypertensive patients, a specific secondary cause can be 
identified. In addition to below mentioned causes, there is also a entity called 
mendelian form of hypertension. 
  
Fig 3.3.1 SECONDARY CAUSES OF HYPERTENSION [5] 
 
 
 
 
 
 
 
3.4 HYPERTENSION AND CARDIOVASCULAR RISK 
Heart disease in systemic hypertensive is due to anatomical and 
functional changes leading to left ventricular hypertrophy, Ischemic heart 
disease, heart failure, arrhythmias and Microvascular disease. Most common 
cause of mortality is Hypertension is heart disease. 
Hypertension is a major risk factor not only for CAD but also for LVH 
and heart failure. Hypertension may contribute to CAD more than is commonly 
realized because hypertensives have more silent ischemia and unrecognized 
myocardial infarctions, and patients with acute myocardial infarction often have 
preexisting hypertension that evaded detection or treatment. Assessment of BP 
is inaccurate during an acute coronary syndrome because of pain-induced BP 
rise or dysautonomia or pump failure decreasing BP. Preexisting hypertension 
increases the case-fatality rate associated with an acute myocardial infarction 
and risk of hemorrhagic stroke is increased during thrombolytic therapy, 
especially when systolic BP exceeds 175 mm Hg. Cardiovascular risk also 
increases dramatically with hypertensive end organ damage.  
 FIG 3.4.1RISK FACTORS INFLUENCING PROGNOSIS IN 
HYPERTENSION[6] 
There is doubling of cardiovascular disease risk for every 20-mmHg 
increase in SBP and 10-mmHg increase in DBP. [7] Persons ranging from 40 to 
89 years of age at increased risk. Data derived from Framingham Heart Study 
have shown that BP between 130–139/85–89 mmHg is associated with greater 
than twofold increased risk of cardiovascular disease (CVD) when compared 
with persons with BP levels lower than 120/80 mmHg.[8]  Greater the BP, higher 
the risk of myocardial infarction, heart failure, chronic kidney disease and 
stroke.[9]  
Framingham CHD risk score calculated from tables published [10] assists 
physicians and hypertension patients in follow up of treatment. 
3.5 HEART FAILURE AND HYPERTENSION 
Heart failure caused most deaths from hypertension before the advent of 
effective drug therapy for hypertension in the late 1950s. Better management 
has substantially reduced hypertension-related deaths from heart failure and 
significantly delayed its onset, but hypertension remains the most common 
cause of heart failure with preserved systolic function. In addition, hypertension 
indirectly leads to systolic heart failure as a major risk factor for myocardial 
infarction. CHF may be related to Left Ventricular (LV) systolic dysfunction, 
LV diastolic dysfunction, or both.  
In individuals with HF symptoms, 40-50% may have preserved LV 
systolic function. They have a high chance of having systemic hypertension, 
Left Ventricular Hypertrophy, isolated diastolic dysfunction. They are also more 
likely to be females. [11] [12] Progression to LV dysfunction can be greatly 
reduced by treatment with ACE Inhibitors, Beta blockers and diuretics. Heart 
failure is preceded by systemic hypertension in 90%. Risk of heart failure is also 
increased 2-3 fold in patients with hypertension. Hypertension in elderly 
individuals is especially important. Heart failure incidence has remained 
unchanged in males and in females, HF has declined over past 50 years.13] But, 
hospitalization due to HF have doubled in the past twenty years [14] probably 
secondary to improvement in therapeutic methods which result in increased life 
expectancy. With increasing proportion of aging population HF may become 
more prevalent in near future. probably become even more prevalent in the 
future as our population ages.               Reducing SBP is uniformly beneficial, 
even though BP targets for Heart Failure have not been established firmly.  
3.6 HEART FAILURE WITH PRESERVED EJECTION FRACTION 
(HFnlEF)      [Diastolic Heart Failure ] 
Diastolic Heart Failure is said to be present when the ejection fraction at 
rest is normal or near normal. In this condition, heart is either normal or small in 
size and heart failure features are present. Left ventricular (LV) hypertrophy 
will be often present and filling of heart is impaired due to altering of LV 
stiffness. There will also be other evidence of LV diastolic Dysfunction. 
Conditions such as Severe Hypertension or Valvular heart like mitral 
regurgitation may be present. Diastolic heart failure may coexist with Systolic 
Heart Failure, especially during exercise 
“Heart failure with preserved systolic function” is a heterogeneous group 
including noncompliant and stiff left ventricle dysfunction (isolated diastolic 
heart failure), dysfunction of cardiac valves, cardiac arrhythmias, RV 
dysfunction, pericardial disease. It is thus a diagnosis of exclusion, and such a 
nonspecific approach can lead to many patients being given a diagnosis of heart 
failure incorrectly. Much controversy has arisen around the best noninvasive 
methods of identifying heart failure caused by isolated diastolic dysfunction, 
with European guidelines suggesting that to make this diagnosis, there should 
be Heart failure symptoms and signs, abnormal LV relaxation, normal (or only 
mildly abnormal) LV systolic function and filling, diastolic stiffness or 
distensibility.[15]  
Such a definition has proven difficult to use in clinical practice. Vasan 
and colleagues have shied away from this strict definition and have suggested 
dividing the diagnosis of diastolic heart failure by the likely probability of the 
diagnosis being correct (definite, probable, or possible). Individuals are 
categorized depending on the absence and presence Heart Failure, with evidence 
of normal systolic function (EF >50%) during a heart failure event, and 
evidence of diastolic dysfunction chiefly from echocardiography. This approach 
was endorsed by the ACC/AHA. [16]  
Heart failure with preserved systolic function was not considered to be 
common in many population based studies, but recent reports from Olmsted 
County (Rochester Epidemiology Project) and a small nested case-control study 
from the Framingham Heart Study in North America suggest this can be as 
common as systolic dysfunction, particularly if the diagnosis of heart failure is 
based on accepting the clinician's opinion or using the Framingham criteria and 
relying on echocardiography at any point during a hospitalization period.[17] [18] 
[19] [20][21] Most of the studies suggest that the probability of the systolic function 
of the left ventricle being preserved in a patient with heart failure is higher in 
the elderly, women, and the obese.[22]  
3.6.1 PROGNOSIS OF HEART FAILURE 
Factors associated with a poorer prognosis include Male sex, old age, 
severe symptoms of Heart Failure, Hypotension, Acute coronary syndrome, 
elevated plasma BNP concentration, hyponatremia, and renal function 
impairment. [23][24][25][26] 
 
3.6.2 CONCLUSION 
The number of people living with Heart Failure syndrome is set to 
increase steeply in the next decades because of an improving prognosis and a 
rapidly aging population. The typical patient is elderly, as likely to be female as 
male, and will be suffering from considerable comorbidities. The direct cost to 
the health care system is substantial and is largely driven by hospitalization 
costs. The epidemiology suggests that efforts to prevent and treat hypertension 
and the other risk factors for coronary artery disease (including obesity, 
diabetes, hyperlipidemia, and cigarette smoking) will at least delay, if not 
prevent, the development of heart failure. Once the syndrome develops, the 
prognosis is poor, particularly in the first months after diagnosis, but has 
improved substantially in the past decades, presumably as a result of better 
diagnosis and therapy with angiotensin-converting enzyme inhibitors and -
blockers. The epidemic of heart failure is already on us and will be a challenge 
for all health care settings for the foreseeable future. Management of Diastolic 
Heart Failure remains empirical and should be oriented towards reduction filling 
pressures of ventricles, at the same time not reducing the cardiac output and 
achieving control of symptoms 
 
Abnormalities of diastolic function that range from asymptomatic heart 
disease to overt heart failure are common in hypertensive patients. An early 
consequence in systemic hypertension is LV Diastolic dysfunction which is 
exacerbated in ischemia and left ventricular hypertrophy. Diastolic function is 
most accurately measured by Cardiac catheterization. Alternatively, non-
invasive methods like echocardiography  and radionuclide angiography are 
used.  
The emergence of this “new” form of HF engendered considerable early 
skepticism, despite growing epidemiologic evidence of its importance. 
Controversy about the significance of HFnlEF has largely but not completely 
abated. Our understanding of this syndrome is incomplete and will continue to 
evolve as the field advances. 
 FIG 3.6.1 SHOWING INCREASED PREVALENCE OF HFNLEF[27] 
 
           The term HFnlEF has been used in current HF management 
guidelines.[28,29] Numerous epidemiologic studies and national HF registries 
have defined the prevalence of HFnlEF in various HF populations and have 
documented a prevalence of 50% to 55%.[30,31-34] The prevalence of HF 
increases with age and similar in men and women (Fig 3.6.2). The prevalence of 
HF with a depressed EF increases with age but is more common in men than in 
women at any age ( Fig 3.6.2), whereas the prevalence of HFnlEF increases 
even more dramatically with age (more than HF with a reduced EF) and is much 
more common in women than in men at any age ( Fig 3.6.2)[35] 
 
FIG 3.6.2 PREVALENCE CHARACTERISTICS OF HFNIEF 
 
3.6.3 Aging  
Although cardiovascular disease may contribute to diastolic dysfunction 
in older people, studies have also suggested that diastolic function deteriorates 
with normal aging.[36] Structural cardiac changes with aging (e.g., increased 
cardiomyocyte size, increased apoptosis with decreased myocyte number, 
altered growth factor regulation, focal collagen deposition) and functional 
changes at the cellular level involving blunted beta-adrenergic responsiveness, 
excitation-contraction coupling, and altered calcium-handling proteins may 
contribute to diastolic dysfunction with normal aging. Some studies have 
suggested that prolonged, sustained endurance training may preserve LV 
compliance with aging and help prevent HF in the elderly.[37] 
3.6.5 Gender  
Along with age, female gender is a potent risk factor for HFnlEF .Indeed, 
there appear to be important age-gender interactions, such that the HFnlEF 
prevalence increases sharply with age in women than prevalence of Heart 
Failure  with a reduced EF.[38] The reasons for the female prominence in 
HFnlEF are not entirely clear, but women have higher vascular and LV systolic 
and diastolic stiffness than men do, and vascular and ventricular stiffness 
increases more dramatically with age in women.[39] Unique coronary vascular 
functional changes in women may also play a role in the pathophysiologic 
process of HFnlEF. 
3.6.6  Hypertension  
Hypertension is the most commonly associated cardiac condition in 
patients with HFnlEF. Chronically increased blood pressure is an important 
stimulus for cardiac structural remodeling and functional changes. The resultant 
hypertensive heart disease is characterized by LV hypertrophy (LVH), 
increasing vascular and ventricular systolic stiffness, impaired relaxation, and 
increased diastolic stiffness, all factors linked to the pathogenesis of HFnlEF.[40] 
In the presence of hypertensive heart disease, ischemia produces exaggerated 
increases in filling pressures, and hypertensive heart disease and ischemic heart 
disease are often present in combination in patients with HFnlEF. Elucidating 
which factors mediate transition to HFnlEF in systemic hypertension needs 
further active investigation. 
3.6.7  Coronary Artery Disease  
The reported prevalence of coronary artery disease or myocardial 
ischemia in patients with HFnlEF varies widely 
 
 
3.6.8 Atrial Fibrillation and Other Rhythm Disturbances  
Whereas atrial fibrillation may cause decompensated HF in patients with 
diastolic dysfunction, diastolic dysfunction (in the absence of HF) is also a risk 
factor for atrial fibrillation.[41] Thus, diastolic dysfunction, atrial fibrillation, and 
HFnlEF are common and related conditions that probably share common 
pathogenic mechanisms in the elderly.  
3.6.9  Obesity  
The chance of developing Heart Failure is increased in obesity In general, 
patients with HFnlEF are more often obese than. Obese individuals have 
increased prevalence of LV diastolic dysfunction is increased in obese persons. 
Increased adiposity not only imposes an adverse hemodynamic load on the heart 
but also is a source of a large number of biologically active peptide and 
nonpeptide mediators, many linked to chronic inflammation. Studies using 
tissue Doppler imaging or invasive LV pressure measurement have reported an 
association between diastolic dysfunction, elevated filling pressures, and 
obesity, even in the absence of a diagnosis of HF.[42]  
3.6.10  Sleep Apnea  
Obstructive sleep apnea is common in patients with HFnlEF risk factors 
(obesity, atrial fibrillation, and hypertension) and in HFnlEF and can contribute 
to symptom severity and probably promote progression of HF. Central sleep 
apnea can occur in association with severe HFnlEF. 
3.6.11  Rarer Causes of Heart Failure with a Normal Ejection  Fraction  
 Hypertrophic cardiomyopathy, infiltrative cardiomyopathy such as 
amyloidosis, valvular disease, and constrictive Pericarditis should always be 
considered in young patients with HFnlEF or patients with other suggestive 
features.  
3.7 LEFT VENTRICULAR HYPERTROPHY AND 
 HYPERTENSION 
Left Ventricular Hypertrophy in systemic hypertension is usually 
“concentric” hypertrophy with myofibrils showing circumferential hypertrophy, 
with contractility either normal or increased, wall thickness relatively increased, 
and end-diastolic volumes either normal or low, relaxation being impaired 
(“diastolic dysfunction”). 
Cardiomyocyte hypertrophy and cardiac fibrosis are the hallmarks of 
pathologic LVH due to pressure overload. LVH in hypertensive patients is 
independent and powerful predictor of morbidity and mortality. The structural 
abnormalities in the hypertensive heart extend beyond myocyte hypertrophy and 
include medial hypertrophy of the intramyocardial coronary arteries and 
collagen deposition leading to cardiac fibrosis.[43] These changes result from 
pressure overload and the neurohormonal activation that contributes to 
hypertension. LVH is also contributed by both hemodynamic and genetic 
factors  
On the electrocardiogram, LVH with strain is a serious harbinger of new-
onset heart failure and heart failure death.[44] Echocardiography detects LVH 
more sensitively than electrocardiography does. Whereas electrocardiographic 
LVH is present in 5% to 10% of hypertensives, echocardiographic LVH is 
present in nearly 30% of unselected hypertensive adults and in up to 90% of 
patients with severe uncontrolled hypertension. Cardiac magnetic resonance 
imaging (MRI) is even more sensitive. [45] 
3.7.1 IMPAIRED CORONARY VASODILATOR RESERVE  
Even in the absence of atherosclerosis, the hypertensive heart has blunted 
or absent coronary vasodilator reserve, leading to subendocardial ischemia 
under conditions of increased myocardial oxygen demand. The combination of 
subendocardial ischemia and cardiac fibrosis impairs diastolic relaxation, 
leading to exertional dyspnea and diastolic heart failure. About 30- 50% of 
persons with stage 1 and 2 systemic hypertension have impaired LV relaxation 
ans more than two-thirds of persons with severe hypertension have abnormal 
LV relaxation.[46]  
Echocardiography is a more sensitive technique than electrocardiography 
for LVH detection. Persons with LVH are twice more likely to suffer from 
premature cardiovascular events or death. Systemic Hypertension if 
aggressively controlled can reverse or regress LVH and thereby reduce 
cardiovascular disease risk. ACE inhibitors have shown to achieve consistent 
reduction in left ventricular mass. In LIFE study, LVH was found to be 
significantly reduced by by a losartan-based based regimen.[47] 
3.8 LARGE-VESSEL DISEASE & HYPERTENSION 
Hypertension constitutes a major risk factor for aortic dissection. 
Systemic Hypertension is present in the overwhelming majority of patients with 
aortic dissection (distal more than proximal dissection), abdominal aortic 
aneurysm, and peripheral arterial disease. One-time abdominal ultrasound 
screening for abdominal aortic aneurysm is recommended after the age of 65 
years in smokers and in those with severe systolic hypertension, and it should be 
performed if aortic pulsations are detected below the umbilicus because most 
abdominal aortic aneurysms occur below the origin of the renal arteries.  
In adults, a diameter of 2.1 cm/m2 has been considered the upper normal 
range in ascending aorta and above this value, aortic root dilatation is said to be 
present. Aortic root dilatation occurs at the sinuses of Valsalva.[48].  Trans-
oesophageal echocardiography is technique of choice for measurement of arch 
of aortic and descending aorta due to better visualization 
3.9  HYPERTENSION AND AGE: 
Systemic Hypertension increases in prevalence along with advancing age. 
More than 50% of persons in 60–69 years of age and three-fourths of those in 
70 years of age and older are affected.[49] Lifetime risk of systemic hypertension 
was found to be 90 % for non-hypertensiv men and women at 55 or 65 years 
who survived to 80–85years of age. [50] Pulse pressure and SBP are powerful 
predictors of cardiovascular disease than DBP in older individuals 
3.10 HYPERTENSION IN WOMEN 
Females exhibit sexual dimorphism in Blood pressure. SBP levels were 
lower in early adulthood Women, while DBP levels were lower in sixth decade. 
DBP is marginally lower in women regardless of age.[51]  Systemic hypertension 
is also less prevalent in women than men. But, hypertension incidence occurs 
more rapidly in women after the fifth decade and is either equal or exceeds men 
in the sixth decade of life.  
3.11 HYPERTENSION AND OBESITY 
Across various populations, hypertension prevalence increases linearly 
with average body mass index. More than half of the cases of hypertension may 
be due to obesity 
Indians have unique features with regard to obesity like abdominal 
adiposity, increase in intra- abdominal and subcutaneous fat, and fat deposition 
in ectopic sites like liver, muscle, etc. Obesity is associated with widely 
prevalent type 2 diabetes mellitus and metabolic syndrome in Asian Indians. 
Based on percentage body fat and morbidity data, The limits of normal BMI 
were narrower and lower in Asian Indians than white Caucasians on the basis of 
percentage of body fat and morbidity data. Consensus Statement for Diagnosis 
of Obesity in asian Indians states Normal BMI: 18.0-22.9 kg/m2, Overweight: 
23.0-24.9 kg/ m2, Obesity: >25 kg/m2.[52] 
Reduction of age related rate of weight gain is the major goal of 
management of both the metabolic syndrome and overweight and obesity. 
3.12 TOBACCO AND HYPERTENSION 
Cigarette smokers have a higher chance of developing large vessel as 
well as small vessel disease. Nearly 90% of peripheral vascular disease and 50% 
of aortic aneurysms are attributed to smoking. Also 20–30% of CAD and 10% 
of stoke are due to cigarette smoking. Cigarette smoking also interacts with 
other cardiac risk factors and leads too increment in risk of CVD 
Risk of second coronary event is reduced within 6-12 months of cessation 
of cigarette smoking. Within first few years of cessation of smoking , risk of 
first MI and death due to CAD also decline After 15 years of abstinence, Risk of 
a new myocardial infarction or death from coronary heart disease in former 
smokers is similar to non- smokers after 15 years of cessation. 
3.13 IMPROVING HYPERTENSION CONTROL 
Systemic hypertension remains an inadequately treated condition, even 
though it is the most common indication for adults to visit a physician,.[53] 
hypertension therapy will be most effective only if the patient is well motivated 
to take anti hypertensive medications and maintain health-promoting 
lifestyle.[54]  
Clinical inertia pn the part of the physician must be overcome. [55] 
Physicians must periodically review their patient files and assess degree 
of compliance and achievement of established goals and treatment. Patients 
needed to informed about their BP during each visit and a written record has to 
be given to them.Physicians should work with other health care professionals in 
order to influence improvement in patient lifestyles and BP control.  
Patient attitudes are greatly influenced by cultural differences, beliefs, 
and previous experiences with the health system.[56] Attitudes of hypertensive 
patients should be understood so as to build trust and communication with 
patients and their families, as cultural beliefs, previous hospital experience 
greatly influence patient attitudes. Furthermore, behind the inherent nature of 
the disease lurks another disquieting feature of the therapy of most 
hypertension; it may not benefit the majority of patients who adhere faithfully to 
their treatment.[57] 
The situation may change for at least three reasons. First, significant 
increases in cardiovascular morbidity and mortality have now been amply 
documented, even in those with levels of blood pressure below 
140/90 mm Hg.[58] Second, blood pressure levels above the assumed normal 
(i.e., 120/80 mm Hg) interact with other cardiovascular risk factors, calling for 
the need to address not only blood pressure but the patient's multiple risk 
factors.[59] Third, and perhaps most importantly, treatment with drugs that have 
almost no side effects can delay, if not prevent, the progression of 
prehypertension into overt hypertension.[60] Beyond these reasons, the potential 
for an inexpensive polypill with antilipemic, antihypertensive, and 
antithrombotic components may soon be realized.[61]  All these reasons are 
amplified by the realization that the prevalence of hypertension continues to 
increase as the population grows fatter and older. 
 FIG 3.13.1[4] ALGORITHM FOR TREATMENT OF HYPERTENSION 
3.14 FOLLOWUP AND MONITORING 
Once antihypertensive drug therapy is initiated, most patients should 
return for follow-up and adjustment of medications at monthly intervals or until 
the BP goal is reached. More frequent visits will be necessary for patients with 
stage 2 hypertension or with complicating comorbid conditions. Serum 
potassium and creatinine should be monitored at least one to two times per year. 
After BP is at goal and stable, follow-up visits can usually be at 3- to 6-month 
intervals. 
Comorbidities such as HF, associated diseases such as diabetes, and the 
need for laboratory tests influence the frequency of visits. Other cardiovascular 
risk factors should be monitored and treated to their respective goals, and 
tobacco avoidance must be promoted vigorously. Low-dose aspirin therapy 
should be considered only when BP is controlled because of the increased risk 
of hemorrhagic stroke when the hypertension is not controlled.[62] 
3.15 ECHOCADIOGRAPHY IN HYPERTENSION 
Echocardiography remains the most frequently used and usually the 
initial imaging test to evaluate all cardiovascular diseases related to a structural, 
functional, or hemodynamic abnormality of the heart or great vessels. Even with 
advances in other cardiovascular imaging modalities, such as cardiac magnetic 
resonance imaging and computed tomography. Whereas electrocardiographic 
LVH is present in 5% to 10% of hypertensives, Echocardiographic LVH is 
present in nearly 30% of unselected hypertensive adults and in up to 90% of 
patients with severe uncontrolled hypertension.  
3.15.1 PRINCIPLE 
Echocardiography uses ultrasound beams reflected by cardiovascular 
structures to produce characteristic lines or shapes caused by normal or altered 
cardiac anatomy in one, two, or three dimensions by M (motion)–mode, two-
dimensional, or three-dimensional echocardiography, respectively. Doppler 
examination and color flow imaging provide reliable assessment of cardiac 
hemodynamics and blood flow.[65]  
Transesophageal echocardiography (TEE) has markedly improved 
resolution of echocardiographic images, including tissue Doppler imaging, three 
dimensional imaging and strain imaging and has enhanced the ability to assess 
systolic and diastolic function.[66]  
Reliable noninvasive hemodynamic evaluation and confident delineation 
of cardiovascular structures by echocardiography have dramatically reduced the 
clinical necessity for hemodynamic cardiac catheterization. Increasingly, 
patients undergo valvular or congenital heart surgery on the basis of an 
echocardiographic diagnosis. Echocardiographic units are also being 
miniaturized to become an extension of a clinician's physical examination.[67] In 
our opinion, the appreciation of cardiac anatomy and hemodynamics by bedside 
echocardiography makes a physician's clinical evaluation, including physical 
examination, more relevant to the care of patients. For all physicians who care 
for patients with a cardiovascular problem, it is essential to know how 
echocardiographic images are obtained, what type of information 
echocardiography can provide, and how it should be used for management. 
Real-time two-dimensional echocardiography produces high-resolution 
images of cardiac structures and their movements. The images are obtained 
from four standard transducer locations by manual rotation and angulation of 
the transducer and quantitative and qualitative measurements regarding cardiac 
dimensions are obtained. [68]  2D echocardiography also helps in providing 
framework for Doppler examination and color flow imaging. With advances and 
clinical experience in three-dimensional and multidimensional 
echocardiographic imaging, visualization and quantitation of cardiovascular 
structure, function, and hemodynamics will improve. It may be feasible in the 
near future for echocardiogram to begin with three-dimensional images. 
 FIG 3.15.1- FOUR STANDARD TRANSDUCER POSITIONS—
PARASTERNAL, APICAL, SUBCOSTAL, AND SUPRASTERNAL—
USED TO VISUALIZE THE HEART AND GREAT VESSELS. 
 
 FIG 3.15.2 – VARIOUS TOMOGRAPHIC ECHOCARDIOGRAPHIC 
IMAGES [69] 
 
3.15.2  M-MODE ECHOCARDIOGRAPHY 
An M-mode recording is used to record the motion of cardiac structures. 
Primary use of M-mode is display of subtle abnormalities of cardiac motion, 
timing of cardiac event and measuring chamber size. Thus, it is important to 
recognize the characteristic M-mode features to understand the 
pathophysiologic mechanisms of cardiovascular disorders. 
3.15.3  DOPPLER ECHOCARDIOGRAPHY  
Doppler echocardiography measures blood flow velocities on the basis of 
the Doppler Effect. Frequency of reflected ultrasound waves (fr) increases when 
the red blood cells are moving toward the source of ultrasound and decreases 
when the red blood cells are moving away. The difference in frequency between 
transmitted sound and reflected sound is the frequency shift or Doppler shift: 
(Δf = fr − fo). Once Δf is calculated, the velocity of red blood cells IS calculated 
as v = Δf  x c/2 fo (c - speed of sound in blood (1540 m/sec). Blood flow 
velocities measured with Doppler echocardiography are used to derive various 
hemodynamic data. 
 
FIG 3.14.3 DIAGRAM OF THE DOPPLER EFFECT [70] 
 
3.15.4  COLOR FLOW IMAGING  
 
FIG 3.14.4   DRAWING ILLUSTRATING HOW COLOR FLOW 
IMAGING IS PERFORMED AND DISPLAYED[71] 
 
Color Doppler is a form of pulsed-wave Doppler displaying blood flow or 
myocardial velocities in various colors (usually red, blue, and green) or their 
combinations, depending on turbulence, velocity, direction. During intracavitary 
flow, blood flow is directed toward the transducer and has positive frequency 
shift and color is coded in red shades, whereas blood flow directed away from 
transducer has negative frequency shift and color is coded in blue shades. 
Abnormal blood flow is easily recognized by combinations of multiple colors 
according to the directions, velocities, and degrees of turbulence. The width and 
size of abnormal intracavitary blood flows are used to evaluate the degree of 
valvular regurgitation or cardiac shunt. Color Doppler is used also for 
determination of diastolic function and timing of intracardiac events. 
3.15.5  TISSUE DOPPLER AND STRAIN IMAGING  
Tissue Doppler imaging (TDI) records the motion of tissue or other 
structures with a velocity or frequency shift much lower than that of blood flow. 
Doppler echocardiography for blood flow measures the velocities of red blood 
cells (velocity usually higher than 20 cm/sec and up to 800 cm/sec in the case of 
valvular disease). However, the velocities of myocardial tissue are much lower 
(<30 cm/sec) but with larger amplitudes than those produced by blood. 
Therefore, pulsed-wave Doppler was modified to record the low velocities of 
myocardial tissue and to reject the high velocities generated by blood flow. TDI 
can also be displayed in color mode. A major limitation of tissue velocity 
recording is that tissue velocities measured by TDI may overestimate or 
underestimate the active component or function of the tissue because of 
translational motion or tethering, respectively. Strain (ϵ) and strain rate imaging 
can overcome this limitation by measuring the actual extent of stretching or 
contraction 
Strain imaging also allows left ventricular (LV) rotational motion, often 
referred to as torsion or twist, to be assessed. The spiral shape of LV myocardial 
fibers results in a complex three-dimensional torsion mechanism for systolic 
contraction and untwisting for diastolic relaxation.[72] degree of torsion or 
twisting appears to be related to aging and diastolic function as well as systolic 
contraction.  
The clinical applications of TDI and strain imaging are increasing and 
provide incremental diagnostic and prognostic value over standard two-
dimensional and blood pool Doppler echocardiography. They have been used 
successfully in assessing regional and global systolic and diastolic function. 
Myocardial strain becomes abnormal during the early stage of myocardial 
ischemia as well as in myopathies and appears to be more sensitive for 
identification of ischemic segments during stress echocardiography.[73-78] TDI is 
nowadays most commonly used to evaluate diastolic function and diastolic 
filling pressures.[79,80] Both strain imaging and TDI allow reliable determination 
of cardiac timing intervals, which is useful in assessing cardiac function[81] and 
LV intraventricular mechanical dyssynchrony.[82-85] 
3.15.6  CHAMBER QUANTITATION  
The American Society of Echocardiography (ASE) has published 
recommendations for chamber quantification with M-mode and two-
dimensional echocardiography. It is recommended that the same normal values 
for chamber dimensions and volumes should be used in both TEE and TTE. [86] 
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, % 
≥55 45-54 30-44 <30 ≥55 45-54 30-44 <30 
 
TABLE 3.15.1  REFERENCE VALUES OF LEFT VENTRICULAR 
FUNCTION[87] 
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LV mass, g 67-162 163-186 187-210 ≥211 88-224 225-258 259-292 ≥293 
 
TABLE 3.15.2 -  REFERENCE VALUES OF LEFT VENTRICULAR 
MASS AND GEOMETRY[88] 
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TABLE 3.15.3-  REFERENCE VALUES LEFT ATRIAL AREAS [89] 
 
 
3.15.7  LEFT VENTRICULAR DIMENSIONS  
Usually, LV dimensions are measured from two-dimensional guided M-
mode echocardiograms of the left ventricle at the level of mitral leaflet tips or 
the papillary muscle by the parasternal view. If no extensive regional wall 
motion abnormalities are present, the LV dimensions measured at the mid-
ventricular level can be used to calculate global LVEF. Left ventricular 
posterior wall and interventricular septum (from the leading edge to the trailing 
edge) are measured from same M-mode echocardiogram. These values are used 
to calculate LV mass.  
 
FIG – 3.15.5  TWO-DIMENSIONAL GUIDED M-MODE 
ECHOCARDIOGRAM OF LEFT VENTRICLE (LV) AT THE 
PAPILLARY MUSCLE LEVEL. 
3.15.8  LEFT ATRIAL SIZE AND VOLUME  
Traditionally, LA dimension is determined from parasternal long-axis 
view during end systole. However, Left atrium size may be underestimated from 
the parasternal view because there may longitudinal enlargement. Therefore, LA 
size must be measured from apical views (Tip of mitral valve to posterior wall 
of LA). However, LA volume is a better measure of LA size and provides better 
prognostic value. LA size or volume is an important determinant of LA 
pressure, diastolic function, and prognosis.[90] 
 
FIG 3.15.6  LEFT ATRIAL VOLUME MEASUREMENT BY BIPLANE 
AREA-LENGTH METHOD [91] 
 
3.15.9  LEFT VENTRICULAR MASS  
Two methods are available for calculation of LV mass from two-
dimensional echocardiography: the biplane area-length method and the 
truncated ellipsoid method. LV mass can also be estimated from measurements 
of LV dimension and wall thicknesses on two-dimensional or M-mode 
echocardiograms. Reasonable determination of LV mass in grams is provided 
by the following formula : 1.04 [ (LVID+PWT+IVST) 3 – LVID3] x 0.8 + 0.6  
(LVID – LV internal dimension, PWT - posterior wall thickness, IVST - 
interventricular septal thickness, 1.04 is the specific gravity of the myocardium, 
and 0.8 being correction factor). . All measurements are made during end 
diastole.  
Three-dimensional imaging has the potential to be the most accurate 
echocardiographic measure for LV volume and mass. Compared with CMR, 
Mor-Avi and colleagues [92] showed that interobserver variability was 37%  
19% of measured LV mass by two-dimensional echocardiography and 7% - 
10% by real-time three-dimensional echocardiography.  
3.15.10  SYSTOLIC FUNCTIONAL PARAMETERS  
Echocardiography can measure several parameters as an expression of 
systolic function of the heart. These parameters are LVEF, fractional shortening, 
stroke volume and cardiac index, systolic tissue velocity of the mitral annulus 
and myocardium, strain, and regional wall motion analysis. 
3.15.11  LEFT VENTRICULAR EJECTION FRACTION  
The most well accepted expression of global LV function is LVEF. LVEF 
is a strong predictor of outcome in all major cardiac conditions, although it has 
many limitations, including load dependency. LVEF is also used to select 
optimal treatment strategies. In clinical practice, LVEF should be measured 
more objectively whenever possible, using volumetric measurements as 
described by the following equation: LVEF = (LVED-LVESV)/LVEDV. 
LVEDV and LVESV are LV end-diastolic volume and end-systolic 
volume, respectively. LVEF can also be calculated from LV dimensions 
measured with M-mode or two-dimensional echocardiography from the mid-
ventricular level using the formula: LVEF = (LVEDD2-LVESD2)/LVEDD2.  
LVEDD and LVESD are end-diastolic dimension and end-systolic dimension, 
respectively. This equation is actually the percentage change in LV area, or 
fractional shortening of the LV short axis. Because the apical long axis normally 
shortens 10% to 15% with systole, an apical correction factor is added on the 
basis of the contractility of the apex: 5% to 7% for normal to hyperdynamic 
apical contraction, 3% for hypokinetic contraction, and 0% for akinetic apex. 
Because three-dimensional echocardiography can provide LV end-diastolic and 
end-systolic volumes closer to those measured by CMR, it will become the 
standard method to calculate LVEF. It can also provide regional LV volume as 
well as the timing of the smallest volume of each region, which may be helpful 
in assessing the synchronicity of LV regional contraction. 
3.15.12  ASSESSMENT OF DIASTOLIC FUNCTION  
 Diastolic function assessment must be an integral part in evaluation of 
cardiac function because about 50% of patients with heart failure have 
preserved LVEF. Currently, echocardiography is the best noninvasive way to 
evaluate diastolic function and to estimate filling pressures. M-mode, two-
dimensional, and Doppler (blood flow, tissue, and color) echocardiography are 
all helpful in evaluating diastolic function. Recently, the ASE and European 
Association of Echocardiography (EAE) released guidelines for assessing 
diastolic function by echocardiography.[93] The following steps will ensure 
comprehensive assessment of diastolic function and the identification of heart 
failure related to diastolic dysfunction:  
1. Look for two-dimensional and M-mode echocardiographic evidence 
suggestive of diastolic dysfunction. Abnormal myocardial relaxation, an 
integral part of diastolic dysfunction, decreases the slope (in M-mode) 
and mitral annulus motion of early diastolic filling and increases LA size. 
LV wall thicknesses are usually but not necessarily increased 
2. Mitral inflow velocities reflect the transmitral pressure gradient, which is 
usually characteristic of various stages of diastolic dysfunction. 
Assessment of ventricular compliance is possible from the configuration 
of mitral inflow velocities. Pulmonary vein flow velocities are also 
helpful. 
3. Myocardial relaxation by TDI can be evaluated. Mitral annulus velocity 
(e′) during early diastole correlates reasonably well with the status of 
myocardial relaxation (tau). 
4. Mitral inflow velocities (E and A), e′, mitral inflow propagation velocity, 
and their combination can estimate LV diastolic filling pressure in rest 
and during exercise. 
 
 
 FIG 3.15.7 LV AND LA PRESSURE RELATIONSHIP AND 
CORRESPONDING MITRAL INFLOW VELOCITIES IN THREE 
DIFFERENT DIASTOLIC FILLING PATTERNS: IMPAIRED 
RELAXATION, NORMAL, AND RESTRICTIVE AND ACTUAL 
DOPPLER RECORDINGS [94] 
LV diastolic filling consists of a series of events that are affected by 
numerous factors, including myocardial relaxation, compliance, cardiac rhythm, 
and pericardial compliance. In normal diastolic function, adequate filling of 
ventricles at rest and during exercise without abnormal increase in diastolic 
pressure or pulmonary venous congestion is ensured. Myocardial relaxation is 
initial diastolic event.[95]   
It is an active energy-dependent process causing LV pressure to decrease 
rapidly after end of contraction leading to mitral valve opening and rapid early 
diastolic filling. Elastic recoil due to normal relaxation of LV is a major 
determinant of early diastolic filling under normal circumstances. Normally, 
75% to 80% of LV filling occurs during this phase. During early diastolic 
filling, LV pressure continues to decrease until completion of myocardial 
relaxation (normally about 100 milliseconds) before rising after reaching 
minimal pressure leading to loss of positive driving force which results in the 
deceleration of mitral inflow. Later, 20% to 25% of LV filling in normal 
subjects is by atrial contraction which produces a positive transmitral pressure 
gradient and inflow. 
 LV filling during various diastolic phases depends on chamber 
compliance, elastic recoil, rate of myocardial relaxation, LA pressure, and 
finally heart rate. The transmitral pressure gradient or the relationship between 
LA and LV pressures is accurately reflected by mitral inflow Doppler 
velocities.[96]   Diastolic filling is classified initially on the basis of peak mitral 
flow velocity of early rapid filling wave (E), peak velocity of the late filling 
wave due to atrial contraction (A), E/A ratio, and MV deceleration time (DT), 
which denotes time interval for the peak E velocity to reach zero baseline  
TDI records the velocity of mitral annulus and has become an essential 
part of diastolic function evaluation by echocardiography.[97] Radial and 
circumferential function can also be assessed with speckle tracking strain 
imaging.[98] 
Comprehensive assessment of diastolic filling by echocardiography 
requires TDI, color M-mode of mitral inflow for propagation velocity, hepatic 
vein Doppler, pulmonary vein Doppler  
3.15.13 GRADING OF DIASTOLIC DYSFUNCTION (OR   
 DIASTOLIC FILLING PATTERN)  
The grading of the diastolic filling pattern (or diastolic dysfunction) is 
based on several parameters. Impaired relaxation is the initial diastolic 
abnormality. With further progression of disease and a mild to moderate 
increase in LA pressure, the mitral inflow velocity pattern appears the same as a 
normal filling pattern (pseudonormalized). With further progression, diastolic 
filling becomes restrictive. Most patients with restrictive filling are symptomatic 
and have a poor prognosis unless the restrictive filling can be reversed by 
treatment. However, restrictive filling may be irreversible and represent the end 
stage of diastolic heart failure. Therefore, diastolic dysfunction can be graded 
according to the diastolic filling pattern.[99] 
Grade 1 (mild): impaired relaxation with normal filling pressure 
Grade 2 (moderate): pseudonormalized mitral inflow  
Grade 3 (severe reversible): reversible restrictive (high filling pressure) 
Grade 4 (severe irreversible): irreversible restrictive (high filling 
pressure) 
 
FIGURE 3.15.8  DIAGRAM OF VARIOUS DOPPLER PARAMETERS 
FOR NORMAL AND ABNORMAL DIASTOLIC FUNCTION (DF) AND 
(DD)[100] 
3.15.14  NORMAL DIASTOLIC FILLING PATTERN  
In normal young subjects, most filling is completed during early diastole 
as LV elastic recoil is vigorous. Thus, the E/A ratio is usually 1.5 or higher, 
DecT is 160 to 240 milliseconds (septal) This vigorous relaxation in normal 
subjects can also be seen as active motion of the mitral annulus away from the 
apex during early diastole in parasternal long-axis and apical four-chamber 
views. 
 
FIGURE 3.15.9 -  MITRAL INFLOW FROM A NORMAL SUBJECT 
With aging, there is slower decline of LV pressure, and filling becomes 
slower, producing a diastolic function pattern similar to grade 1 dysfunction. At 
roughly the age of 65 years, E velocity ia almost equal to A velocity and at more 
than 70 years of age, E/A ratio is less than 1.0. Similar changes are shown in 
pulmonary venous flow velocities  
In Grade 1 LVDD or mild diastolic dysfunction, there is decrease in 
Mitral E velocity and increase in A velocity, producing an E/A ratio < 1 and DT 
is prolonged. Typical cardiac conditions that produce mild diastolic dysfunction 
are LV hypertrophy, HCM, and myocardial ischemia or infarction as well as 
aging.  
In grade II LVDD or moderate diastolic dysfunction, there is 
pseudonormalized mitral flow filling pattern and it is better evaluated by TDI. 
In Grade 3-4 Diastolic Dysfunction or Severe Diastolic Dysfunction, 
there is increase in E velocity, decrease in A velocity (but markedly less than E) 
with an E/A ratio > 2 and DT is shortened (<160 milliseconds) 
3.15.15 CLINICAL APPLICATIONS OF DIASTOLIC            
FUNCTION ASSESSMENT  
1. Estimation of filling pressures at rest and with exercise 
2. Diagnosis of diastolic heart failure, cardiomyopathy, and  constrictive 
pericarditis. 
3. Powerful prognostic indicators for various conditions [ 101-104] 
Therefore, assessment of the diastolic filling pattern allows estimation of 
LV filling pressures and compliance and relaxation so that optimal treatment 
strategies can be offered to symptomatic patients with diastolic dysfunction. 
 
 
 
 
 
 
  
 
 
 
MATERIALS AND 
METHODS 
4. MATERIALS AND METHODS 
4.1   STUDY DESIGN AND PARTICIPANTS 
Patients with systemic hypertension were recruited from Government 
Royapettah hospital hypertension clinic as outpatients. This study was a single 
center cross sectional observational study. A total of 100 patients (55 males and 
45 females) who met inclusion and exclusion criteria were included in to study 
after obtaining formal written and oral consent. Patients aged more than 65 
years were excluded as age related diastolic dysfunction is more common. 
Patients aged between 20 and 65 years who had already been diagnosed with 
systemic hypertension were included. People with history of heart disease and 
any other comorbid conditions were excluded The ethical committee approval 
was obtained before starting the study. The results and observations were 
analyzed statistically. The study was from June 2012 to November 2012 
4.2 PROCEDURES AND OUTCOME MEASURES 
Blood pressure was measured by the conventional cuff method at the time 
of echocardiographic examination. Patients with Controlled Blood pressure 
were defined as those with systolic blood pressure (SBP) < 140 mmHG and 
diastolic blood pressure (DBP) <90 mmHg . Inadequate BP control was defined 
as thoses with systolic blood pressure (SBP)  140 mmHG and/or diastolic 
blood pressure (DBP) 90 mmHg, as per JNC 7 guidelines. The patient’s age, 
height and weight were also recorded at that time. BMI classification was done 
according to Consensus Statement for Diagnosis of Obesity, Abdominal Obesity 
and the Metabolic Syndrome for Asian Indians and Recommendations for 
Physical Activity, Medical and Surgical Management.[1]  As per the consensus 
Statement , Normal BMI was 18.0-22.9 kg/m2, Overweight: 23.0-24.9 kg/ m2, 
Obesity: >25 kg/m2 in Asian Indians. Examinations were performed by M-
Mode echocardiography and Doppler imaging with the Mind ray® diagnostic 
ultrasound system to assess cardiac function and structural changes 
The following left ventricular structural and aortic parameters were 
measured by M-mode echocardiography- left ventricular end-diastolic and end-
systolic dimension, inter-ventricular septal thickness, posterior wall thickness, at 
level of chordae tendinae and aortic root diameter was taken at the level of 
Sinuses of Valsalva. Left ventricular mass using linear method calculated by 
using the formula :  Left  ventricular mass = 0.8 ( 1.04 x  [PW+VS+LVDd]3-
LVDd3)+ 0.6, where LVDd represents left ventricular end diastolic dimension, 
VS represents interventricular septal thickness and PW represents posterior wall 
thickness. LV ejection fraction was determined by using teichholz’s method .A 
threshold of 55% was used to indicate left ventricular systolic dysfunction. 
Aortic diameter and Left atrial diameter was recorded in apical four chamber 
view. 
The velocity of transmitral blood flow was recorded by conventional 
Doppler echocardiography for assessing left ventricular (LV) diastolic function. 
Transmitral blood flow was recorded at the apical transducer position, so that 
sample volume was situated between the mitral leaflet tips. E/A was determined 
after recording the peak velocity of early transmitral blood flow (E) and the 
peak velocity of late transmitral blood flow. Recording of Mitral valve 
Deceleration time was also recorded. Patients were defined as having aortic root 
dilatation if the AR(aortic root diameter)/M2 > 2.1 as per European society of 
echocardiography guidelines.[2] 
Patients with LV diastolic dysfunction were defined as those with MV 
(E/A) < 1.0 with prolonged deceleration time (DT) ( >240 ms) and those with 
MV (E/A) > 2.0 with shortened deceleration time (DT) (< 160 ms). [3] 
4.3 STATISTICAL ANALYSIS 
After acquiring the complete set of data and preparing the master chart, 
statistician working in another facility was approached. The data was analysed 
with Statistics Products Services Solutions (SPSS)® software for windows with 
age, sex, duration, control of hypertension, tobacco use, body mass index, left 
ventricular mass, left ventricular diastolic function, left atrial area and aortic 
root diameter as variables. A chi squared test was used to analyze the 
probability of differences between the groups and p<0.05 was taken to be 
statistically significant in all calculations. Graphs were prepared using MS excel 
software® 
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Chi – Square test 
 value df Asymp.Sig 
Pearson Chi-
square 
9.521 1 .002 
 
 
 
 
 
 
LV MASS GRADING AND SEX 
 
 
Chi – Square test 
 value df Asymp.Sig 
Pearson Chi-
square 
9.7631 3 .021 
 
 
MASS AND DURATION OF HYPERTENSION 
 
LV MASS GRADING AND DURATION OF HYPERTENSION 
 
Chi – Square test 
 value df Asymp.Sig 
Pearson Chi-square 22.292 6 .001 
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LV DIASTOLIC FUNCTION AND AGE 
 
 
Chi – Square test 
 value df Asymp.Sig 
Pearson Chi-
square 
14.349 3 .002 
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FIG 5.1:   Left ventricular hypertrophy in parasternal long and short axis view 
 
 
 
FIG 5.2: M-mode view showing normal LV diastolic function  
 
 
FIG5.3: M-mode view showing Grade I LVDD  
( E velocity is decreased, A velocity is increased , DT prolonged)  
 
FIG 5.4: M-mode view showing Grade II LVDD ( pseudonormalization) 
 
FIG 5.5: M-mode view showing Grade III LVDD  
( E velocity markedly increased and A velocity markedly decreased, DT 
shortened) 
 
 
FIG 5.6: Apical four chamber view showing Left atrial enlargemet along with 
LVH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION  
 
6. DISCUSSION 
In our study, there were almost equal numbers of male and female 
participants. 35% of patients were in the age group of 41 to 50 years followed 
by 29% of patients in the age group of 51-60 years. 70 % of the patients had 
duration of hypertension for less than 5 years. 
It is important to note that 74% of patients had inadequate control of 
Blood Pressure (defined as SBP 140 mmHg and/or DBP 90 mmHg at the 
time of echocardiographic examination as per JNC7 guidelines for goal of 
therapy). The most important causes for inadequately controlled BP are 
inappropriate drug doses or drug combinations and improper lifestyle. 
19% of the study population were tobacco users of which 16% were 
females. According to Mishra et al  consensus statement for classification of 
obesity by BMI, 58% were obese and 16% were overweight. This is to 
emphasize the fact that Hypertension is a feature of metabolic syndrome. 
There was only 1 patient with aortic root dilatation and 7 patients had 
echocardiographically enlarged left atrium.  
64% of patient had echocardiographic abnormality of left ventricle. 50% 
of sample group had LV diastolic dysfunction while 41% had abnormal LV 
mass ( defined as value > 163g in females and >224g in males). 27% of 
hypertensives had both abnormal LV mass and LV diastolic dysfunction. 
Approximately 51% had mildly abnormal LV mass and approximately 24% 
each had moderately and severely abnormal LV mass. Echocardiogram was 
found to be more sensitive in detectind abnormal LV mass as anticipated 
It was noted from our observation that with increasing age , there was 
proportional increase in LV mass ( from 33% in 31-40 age group to 47% in 61-
65 age group ) which is along the expected lines. 
One of the important implications of our study was the influence of sex 
over LV mass. 27% of male hypertensives had abnormal LV mass while it was 
58% for female hypertensives. Overall 63% of those with abnormal LV mass 
were female hypertensives and it was statistically very significant. 
Even when the duration of hypertension was less than 5 years, 37% of 
hypertensives had abnormal LV mass of which 50% was mild. When the 
duration of hypertension was more than 10 years, 70% of patients had abnormal 
LV mass of which statistically significant 71% had severely abnormal LV mass. 
90% of those who had abnormal LV mass were tobacco users and 58% of 
patients with inadequately controlled hypertension were males. 61% of females 
with inadequate control of hypertension had abnormal LV mass. 
With advancing age, we observed proportional increase in the incidence 
of diastolic dysfunction from 33% in 31-40 age group to 48% in 50-60 age 
group to 93% in 61-65 age group. We found statistically significant diastolic 
dysfunction with increasing age that could probably be explained by age related 
myocardial stiffening. 
Both males and females almost equally had LV diastolic dysfunction and 
as anticipated LV diastolic dysfunction increased with increased in the duration 
of hypertension. 
57% of obese hypertensives had LV diastolic dysfunction and 45% of 
obese hypertensives had abnormal LV mass. The independent role of obesity 
causing diastolic dysfunction has to be examined further with equal recruitment 
of obese and non obese individuals. 
 
 
 
LIMITATIONS: 
The following was found to be the limitations of the study 
 The sample size was small and further studies with larger number of 
people  in multi centers representing different ethnic groups have to be 
done to verify the results. 
 Majority of participants were obese, had inadequate BP control, non-
tobacco user and equal proportion on BMI, BP control and tobacco and 
non tobacco use should have been tested. 
 Tissue Doppler Imaging which is ideal for evaluating LV diastolic 
dysfunction should have used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
7. CONCLUSION 
 Half of the study group – asymptomatic hypertensives- had evidence of 
LV diastolic dysfunction. This emphasizes the role of screening 
asymptomatic hypertensives for LV diastolic function, as diastolic 
dysfunction is a fore runner of heart failure in future 
 
 According to our study, Female sex is a risk factor for developing 
abnormal LV mass which has to be clarified with further larger sample 
size recruitment. 
 
 Even a short duration of hypertension i.e., less than 5 years results in 
abnormal LV mass in one third of patients. Hence, earlier achievement of 
target BP helps in preventing the progression of end organ damage. 
 
 Most of those who had abnormal LV mass were tobacco users. Therefore, 
influence of tobacco over LV mass has to further scrutinized 
 
 Two-thirds of the study population were obese and two-thirds of them 
had LV diastolic dysfunction. This underlines the importance of obesity 
as a risk factor for hypertension and heart failure. 
 
 Importance of life style education and compliance of drugs is implied by 
the fact that three-fourths of hypertensives had uncontrolled BP 
 
 The study reiterates the fact that there is a proportional age related 
increased incidence of LV diastolic dysfunction and abnormal LV mass 
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ANNEXURES 
DATA COLLECTION SHEET 
NAME  : AGE /SEX : OP. NO 
ADDRESS: OCCUPATION: 
HYPERTENSION DETAILS 
DURATION ANTI HYPERTENSIVE DRUGS 
TOBACCO USE:         YES / NO Height(cm): Weight (Kg): 
BP 
(mmHg): 
Anti-Hypertensive Drug details: Blood 
Glucose 
(mg/dl) 
Blood urea 
(mm/dl) 
Serum 
creatinine 
(mg/dl) 
ECG Chest X-Ray 
 
ECHOCARDIOGRAPHY REPORT 
LVIDd LVIDS EF Left Atrial Area 
IVd IVs Aortic root 
Diameter 
Flow abnormalities 
PWd PWs Left Atrial 
diameter 
RWMA : 
YES/NO 
 
MV (E) MV (A) E/A MV DecT 
REMARKS 
 
 
 
 
 
 
PARTICIPANT CONSENT FORM 
 
 
 
Participant’s name:                                            Address: 
 
 
Title of the project: ECHOCARDIOGRAPHIC CHANGES ASSOCIATED 
WITH SYSTEMIC HYPERTENSION IN HYPERTENSIVE PATIENTS IN 
GOVERNMENT ROYAPETTAH HOSPITAL, CHENNAI – AN 
OBSERVATIONAL STUDY 
 
 
The details of the study have been provided to me in writing and explained to 
me in my own language. I confirm that I have understood the above study and 
had the opportunity to ask questions. I understand that my participation in the 
study is voluntary and that I am free to withdraw at any time, without giving 
any reason, without the medical care that will normally be provided by the 
hospital being affected. I agree not to restrict the use of any data or results that 
arise from this study provided such a use is only for scientific purpose(s). I have 
been given an information sheet giving details of the study. I fully consent to 
participate in the above study. 
 
 
 
 
 
Signature of the participant: ______________________ 
 
 
Date: _____________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
S.NO PATIENT'S NAME AGE SEX DURATION(YEARS)
TOBAC
CO BMI
BMI
GRADING BP SEVERITY AR(cm) AR /M2
AORTIC
ROOT
DILATATIO
N
LA(cm) LVIDd(cm) LVIDs(cm) IVd(cm) IVs(cm) PWd(cm) PWs(cm)
LV
MASS(g) LV MASS
LV MASS
GRADING EF(%) LAA(cm2) LAE MV E MV A MV E/A
MV
DecT(MS)
LV
DIASTOLIC
FUNCTION
1 ASMATHUNISHA 62 F 6 NO 32.05 OBESE 130/80 CONTROLLED 3.00 1.23 NO 2.60 4.10 2.40 1.00 1.40 1.50 1.70 182.00 ABNORMAL MILD 72 13.20 NORMAL 0.76 1.00 0.75 288 ABNORMAL
2 LAKSHMI 38 F 2 NO 27.39 OBESE 130/90UNCONTROLLED 2.61 1.19 NO 2.74 4.30 2.90 1.20 2.70 1.40 1.60 208.00 ABNORMALMODERATE 80 14.22 NORMAL 0.68 0.84 0.81 268 ABNORMAL
3 SELVARAJ 64 M 12 NO 21.87 NORMAL 150/100UNCONTROLLED 3.11 1.94 NO 3.10 5.10 2.80 1.50 2.10 1.50 1.70 332.00 ABNORMAL SEVERE 69 15.91 NORMAL 1.25 1.33 0.64 290 ABNORMAL
4 SASIKUMAR 35 M 0.6 NO 19.14 NORMAL 150/90UNCONTROLLED 3.23 1.26 NO 2.80 4.90 2.80 1.40 2.80 1.60 1.80 313.00 ABNORMAL SEVERE 74 16.90 NORMAL 1.02 0.54 1.88 154 ABNORMAL
5 BALASUNDARAM 49 M 1 YES 28.05 OBESE 120/80 CONTROLLED 3.30 1.24 NO 2.70 4.50 2.70 1.20 1.80 1.00 1.30 175.00 NORMAL NORMAL 71 15.29 NORMAL 0.78 1.09 0.72 264 ABNORMAL
6 INDRA 43 F 5 NO 29.77 OBESE 130/80 CONTROLLED 3.41 1.42 NO 3.00 5.00 3.10 1.10 1.50 0.90 1.20 170.00 ABNORMAL MILD 68 18.00 NORMAL 1.18 0.80 1.47 138 NORMAL
7 AMBUJAM 56 F 2 NO 25.91 OBESE 150/90UNCONTROLLED 2.75 1.27 NO 2.96 4.50 3.00 1.10 1.40 0.90 1.10 153.00 NORMAL NORMAL 61 16.70 NORMAL 0.90 0.82 1.10 120 NORMAL
8 KAVERI 65 F 1 YES 28.69 OBESE 130/90UNCONTROLLED 3.82 1.65 NO 2.90 4.60 2.80 1.00 1.50 0.90 1.20 148.00 NORMAL NORMAL 65 14.30 NORMAL 0.90 1.16 0.78 288 ABNORMAL
9 KHALEEL 63 M 12 NO 29.13 OBESE 140/96UNCONTROLLED 3.31 1.38 NO 2.70 4.90 3.30 1.20 1.60 0.80 1.10 176.00 NORMAL NORMAL 61 17.70 NORMAL 0.71 0.91 0.78 290 ABNORMAL
10 PARTHASARATHY 63 M 14 NO 34.29 OBESE 140/90UNCONTROLLED 3.30 1.26 NO 2.80 5.30 3.60 1.10 1.70 1.10 1.40 228.00 ABNORMAL MILD 61 19.50 NORMAL 0.60 1.06 0.57 292 ABNORMAL
11 SURESHBABU 33 M 2 YES 28.89 OBESE 138/84 CONTROLLED 3.00 1.03 NO 3.50 5.10 3.10 0.90 1.30 0.80 1.20 152.00 NORMAL NORMAL 68 15.35 NORMAL 1.33 1.01 1.31 132 NORMAL
12 GOPAL 43 M 3 NO 25.09 OBESE 120/90UNCONTROLLED 3.14 1.12 NO 2.60 4.20 2.00 1.20 1.50 1.20 1.50 178.00 NORMAL NORMAL 78 17.16 NORMAL 1.02 0.68 1.50 138 NORMAL
13 JAISANKAR 43 M 6 NO 30.48 OBESE 130/80 CONTROLLED 3.40 1.22 NO 2.90 5.10 2.80 1.00 1.50 1.00 1.30 188.00 NORMAL NORMAL 78 18.00 NORMAL 1.29 1.04 1.24 114 NORMAL
14 BAASHA 52 M 5 NO 28.48 OBESE 130/80 CONTROLLED 3.60 1.42 NO 4.40 5.30 2.80 1.10 1.80 1.00 1.30 214.00 NORMAL NORMAL 69 24.30 ABNORMAL 0.89 0.68 1.31 130 NORMAL
15 MOHAMMED 65 M 1 NO 25.81 OBESE 136/90UNCONTROLLED 3.90 1.62 NO 2.70 4.40 2.40 1.20 1.90 1.10 1.30 180.00 NORMAL NORMAL 72 13.40 NORMAL 0.78 1.22 0.64 288 ABNORMAL
16 SULTAN 63 M 2 NO 26.14 OBESE 160/100UNCONTROLLED 3.42 1.44 NO 3.20 5.10 2.60 1.20 1.80 0.90 1.20 201.00 NORMAL NORMAL 79 18.00 NORMAL 0.58 0.88 0.66 288 ABNORMAL
17 SHAKEELA BANU 39 F 0.6 NO 32.47 OBESE 130/90UNCONTROLLED 3.30 1.37 NO 3.00 5.10 2.40 0.90 1.40 0.80 1.10 152.00 NORMAL NORMAL 66 18.00 NORMAL 1.03 0.81 1.27 120 NORMAL
18 ANNAMMA 46 F 0.8 NO 34.13 OBESE 142/90UNCONTROLLED 2.92 1.22 NO 3.00 4.60 2.70 0.90 1.40 0.80 1.10 128.00 NORMAL NORMAL 72 17.00 NORMAL 0.99 0.94 1.05 150 NORMAL
19 CHOODAMANI 38 F 1 NO 26.30 OBESE 130/80 CONTROLLED 3.00 1.23 NO 3.00 5.10 3.10 1.00 1.50 0.80 1.10 163.00 ABNORMAL MILD 68 15.60 NORMAL 1.04 0.71 1.47 138 NORMAL
20 BHUVANESHWARI 44 F 0.5 NO 27.05 OBESE 140/80 CONTROLLED 2.80 1.17 NO 3.80 4.80 2.70 1.10 1.70 0.90 1.20 170.00 ABNORMAL MILD 76 22.00 ABNORMAL 1.03 0.51 2.04 156 ABNORMAL
21 CHANDRAKALA 31 F 1 NO 19.22 NORMAL 150/90UNCONTROLLED 2.63 1.05 NO 2.60 4.30 2.70 0.90 1.50 0.80 1.20 114.00 NORMAL NORMAL 67 15.80 NORMAL 1.28 1.03 1.24 108 NORMAL
22 TAMILSELVI 43 F 12 NO 21.63 NORMAL 160/100UNCONTROLLED 3.11 1.24 NO 3.10 4.70 2.60 0.90 1.60 0.80 1.10 251.00 ABNORMAL SEVERE 75 17.00 NORMAL 0.90 0.63 1.42 114 NORMAL
23 LAKSHMI 50 F 2 NO 30.41 OBESE 130/90UNCONTROLLED 3.10 1.27 NO 3.10 4.60 2.70 1.10 1.90 1.00 1.40 170.00 ABNORMAL MILD 72 21.40 ABNORMAL 0.99 1.23 0.80 256 ABNORMAL
24 CHARLES 37 M 4 NO 19.14 NORMAL 180/98UNCONTROLLED 3.00 1.17 NO 3.20 4.60 3.00 1.00 1.40 1.00 1.40 159.00 NORMAL NORMAL 70 17.00 NORMAL 0.85 0.78 1.10 78 NORMAL
25 VIJAY 37 M 0.6 NO 23.22 OVERWEIGHT170/100UNCONTROLLED 3.30 1.19 NO 3.40 4.20 2.60 1.00 1.60 1.10 1.40 147.00 NORMAL NORMAL 70 20.10 NORMAL 0.73 0.55 1.30 96 NORMAL
26 MALLIKA 45 F 1 NO 20.23 NORMAL 140/90UNCONTROLLED 3.54 1.49 NO 2.60 5.10 2.90 1.20 1.60 1.10 1.40 227.00 ABNORMAL SEVERE 73 16.30 NORMAL 0.60 0.84 0.81 272 ABNORMAL
27 IQBAL 52 M 3 NO 17.84 NORMAL 130/80 CONTROLLED 3.00 1.11 NO 3.10 4.70 2.80 1.00 1.60 1.10 1.50 164.00 NORMAL NORMAL 72 15.30 NORMAL 0.72 0.66 1.08 96 NORMAL
28 PRABHAKAR 42 M 2 NO 26.50 OBESE 140/94UNCONTROLLED 3.60 1.42 NO 3.90 4.50 3.00 1.00 1.60 1.00 1.30 153.00 NORMAL NORMAL 62 22.00 ABNORMAL 0.80 0.50 1.50 174 NORMAL
29 VALLIKANNU 56 M 5 NO 23.11 OVERWEIGHT 132/90UNCONTROLLED 2.90 1.28 NO 2.90 4.10 2.60 0.90 1.90 1.00 1.40 118.00 NORMAL NORMAL 66 13.70 NORMAL 0.63 0.82 0.78 264 ABNORMAL
30 SELVAM 62 M 5 YES 21.87 NORMAL 150/80UNCONTROLLED 4.00 1.56 NO 3.30 5.00 3.20 1.00 1.70 1.00 1.40 182.00 NORMAL NORMAL 67 25.00 ABNORMAL 0.50 0.89 0.60 284 ABNORMAL
31 KARUPPIAH 62 M 0.3 NO 28.07 OBESE 130/90UNCONTROLLED 3.74 1.23 NO 3.86 5.40 3.30 1.20 1.90 1.20 1.50 264.00 ABNORMALMODERATE 72 25.15 ABNORMAL 0.77 0.94 0.82 296 ABNORMAL
32 GOWRI 40 F 1 NO 25.55 OBESE 140/84UNCONTROLLED 3.10 1.50 NO 2.90 4.60 2.60 0.80 1.50 0.80 1.10 118.00 NORMAL NORMAL 73 17.00 NORMAL 0.90 0.97 0.79 264 ABNORMAL
33 LAKSHMI 46 F 2 NO 29.97 OBESE 120/80 CONTROLLED 5.40 2.25 YES 3.60 4.80 2.40 0.90 1.20 1.00 1.40 159.00 NORMAL NORMAL 68 13.20 NORMAL 0.76 1.00 0.76 258 ABNORMAL
34 DEIVAANAI 47 F 3 NO 23.51 OVERWEIGHT 140/90UNCONTROLLED 2.90 1.06 NO 3.30 4.70 2.60 1.00 1.50 1.00 1.30 164.00 ABNORMAL MILD 75 16.00 NORMAL 0.80 0.73 1.20 132 NORMAL
35 PARVATHY 53 F 7 NO 21.78 NORMAL 140/90UNCONTROLLED 2.80 1.03 NO 2.60 4.60 2.60 0.90 1.30 1.40 1.70 193.00 ABNORMALMODERATE 75 14.90 NORMAL 1.03 0.76 1.35 190 NORMAL
36 KUMAR 46 M 2 YES 26.77 OBESE 158/92UNCONTROLLED 3.33 1.24 NO 3.60 4.80 2.70 1.10 1.60 1.10 1.40 194.00 NORMAL NORMAL 76 15.40 NORMAL 0.76 0.64 1.20 72 NORMAL
37 THANGAM 38 F 2 NO 20.93 NORMAL 154/90UNCONTROLLED 2.84 1.21 NO 3.00 4.20 2.60 1.30 1.00 1.10 1.50 178.00 ABNORMAL MILD 70 17.00 NORMAL 0.61 0.75 0.80 272 ABNORMAL
38 REGINA 43 F 15 NO 22.50 NORMAL 160/90UNCONTROLLED 2.80 1.21 NO 3.10 4.30 2.80 1.00 1.30 1.00 1.30 142.00 NORMAL NORMAL 70 16.50 NORMAL 0.88 0.70 1.26 84 NORMAL
39 VENKATESAN 53 M 1 YES 24.91 OVERWEIGHT 130/80 CONTROLLED 3.00 1.11 NO 3.50 4.50 2.40 1.20 1.60 1.00 1.40 175.00 NORMAL NORMAL 60 17.00 NORMAL 0.76 0.64 1.20 150 NORMAL
40 DILIP, 31 M 1 YES 24.67 OVERWEIGHT 138/90UNCONTROLLED 3.15 1.14 NO 3.27 4.80 3.30 1.40 1.90 1.20 1.50 246.00 ABNORMAL MILD 60 14.80 NORMAL 0.78 0.52 1.39 102 NORMAL
41 MALLIKA 48 F 3 NO 32.89 OBESE 140/100UNCONTROLLED 3.90 1.71 NO 3.00 5.00 3.20 1.60 1.90 0.80 1.10 158.00 NORMAL NORMAL 64 20.10 ABNORMAL 0.61 0.75 0.80 258 ABNORMAL
42 VIJAYALAKSHMI 43 F 12 NO 27.83 OBESE 120/80 CONTROLLED 3.27 1.38 NO 3.75 4.50 3.10 1.70 2.20 1.30 1.60 276.00 ABNORMAL SEVERE 58 18.77 NORMAL 0.97 0.81 2.20 114 ABNORMAL
43 IRUDHAYARAJ 49 M 3 YES 26.77 OBESE 126/90UNCONTROLLED 2.85 1.06 NO 3.02 4.80 2.90 1.20 1.50 1.20 1.50 219.00 NORMAL NORMAL 70 19.80 NORMAL 0.94 0.56 1.67 144 NORMAL
44 SHANKAR 57 M 2 YES 23.42 OVERWEIGHT 130/90UNCONTROLLED 3.10 1.21 NO 3.00 4.70 2.80 1.00 1.40 1.20 1.60 187.00 NORMAL NORMAL 70 16.50 NORMAL 1.14 0.84 1.35 96 NORMAL
45 SARAVANNAN 60 M 4 YES 25.60 OBESE 160/100UNCONTROLLED 3.40 1.18 NO 3.80 4.80 2.40 1.20 1.80 1.40 1.70 246.00 ABNORMAL MILD 70 18.25 NORMAL 0.60 1.70 0.75 296 ABNORMAL
46 RAJKUMAR 40 M 0.6 NO 22.49 NORMAL 150/90UNCONTROLLED 3.10 1.07 NO 3.20 4.90 3.20 1.00 1.40 1.00 1.30 212.00 NORMAL NORMAL 63 18.50 NORMAL 1.08 0.62 1.75 150 NORMAL
47 ANBUCHEZIAN 41 M 1 YES 28.07 OBESE 176/100UNCONTROLLED 3.20 0.97 NO 3.60 4.30 2.70 1.10 1.60 1.10 1.40 163.00 NORMAL NORMAL 68 18.23 NORMAL 1.10 0.68 1.19 96 NORMAL
48 SEELI 57 F 10 YES 29.97 OBESE 160/90UNCONTROLLED 3.10 1.30 NO 3.30 4.90 2.70 1.10 1.60 1.10 1.50 200.00 ABNORMALMODERATE 76 19.20 NORMAL 1.15 0.78 1.47 120 NORMAL
49 MAHESWARI 31 F 0.3 NO 22.22 NORMAL 130/80 CONTROLLED 2.37 1.05 NO 2.50 4.20 2.50 0.80 1.00 0.90 1.30 110.00 NORMAL NORMAL 73 12.21 NORMAL 0.80 0.73 1.10 96 NORMAL
50 PAAVADAI 51 M 2 NO 21.05 NORMAL 126/84 CONTROLLED 2.67 0.97 NO 2.99 4.40 2.57 0.80 1.20 0.80 1.10 215.00 NORMAL NORMAL 73 13.04 NORMAL 1.37 0.89 1.54 174 NORMAL
51 CHANDRAKUMAR 63 M 1 NO 27.64 OBESE 120/90UNCONTROLLED 2.94 1.04 NO 4.52 5.30 5.70 1.10 1.40 1.10 1.50 228.00 ABNORMAL MILD 68 18.25 NORMAL 0.96 0.85 1.12 150 NORMAL
52 KRISHNAN 55 M 1 NO 23.22 OVERWEIGHT 140/90UNCONTROLLED 2.78 1.01 NO 3.30 4.10 2.90 1.10 1.20 0.90 1.20 132.00 NORMAL NORMAL 61 11.26 NORMAL 0.71 0.92 0.78 256 ABNORMAL
53 KOIKILA 52 F 0.2 NO 22.48 NORMAL 132/94UNCONTROLLED 3.40 1.42 NO 3.90 4.90 3.30 1.20 1.50 1.20 1.50 389.00 ABNORMAL SEVERE 60 13.00 NORMAL 0.88 0.96 0.71 278 ABNORMAL
54 RAJASEKAR 55 M 5 NO 23.53 OVERWEIGHT150/112UNCONTROLLED 3.25 1.12 NO 3.48 4.60 3.50 1.10 0.83 0.90 1.30 159.00 NORMAL NORMAL 70 15.34 NORMAL 0.96 0.71 1.40 144 NORMAL
55 AMARAVATHY 59 F 0.6 NO 21.91 NORMAL 120/80 CONTROLLED 2.41 1.10 NO 2.49 4.30 2.60 0.80 1.20 1.00 1.50 123.00 NORMAL NORMAL 70 17.63 NORMAL 1.09 0.92 1.18 180 NORMAL
56 MALLIGA 53 F 4 NO 22.51 NORMAL 140/80 CONTROLLED 2.36 1.02 NO 3.49 4.30 2.90 0.80 1.00 0.80 1.20 105.00 NORMAL NORMAL 61 13.17 NORMAL 1.26 1.08 0.80 288 ABNORMAL
57 VIJAYBABU 45 M 7 NO 26.57 OBESE 140/90UNCONTROLLED 2.90 1.03 NO 3.14 5.10 3.30 1.00 1.20 1.00 1.30 188.00 NORMAL NORMAL 64 16.93 NORMAL 1.01 0.76 1.33 168 NORMAL
58 MUNIYAMMAL 55 F 8 NO 29.21 OBESE 180/100UNCONTROLLED 3.00 1.37 NO 3.65 4.50 2.70 1.10 1.40 1.00 1.30 164.00 ABNORMAL MILD 69 15.17 NORMAL 0.47 0.93 0.54 294 ABNORMAL
59 ESWARAN 56 M 1 NO 34.57 OBESE 156/88UNCONTROLLED 3.58 1.33 NO 4.42 5.30 3.00 1.10 1.60 1.20 1.60 242.00 ABNORMAL MILD 73 17.66 NORMAL 0.89 0.97 0.82 270 ABNORMAL
60 SEKAR 54 M 5 NO 26.35 OBESE 150/90UNCONTROLLED 2.87 1.08 NO 3.68 4.30 2.80 1.00 1.30 0.90 1.30 133.00 NORMAL NORMAL 65 15.67 NORMAL 0.98 0.77 1.27 162 NORMAL
61 SRINIVASAN 45 M 0.1 NO 26.93 OBESE 120/80 CONTROLLED 2.73 0.97 NO 3.03 4.00 2.50 1.00 1.20 0.90 1.40 118.00 NORMAL NORMAL 68 15.66 NORMAL 0.80 0.91 0.80 264 ABNORMAL
62 VINCENT 38 M 3 NO 24.02 OVERWEIGHT 130/86 CONTROLLED 2.91 1.04 NO 3.19 5.10 3.70 1.10 1.50 1.10 1.40 214.00 NORMAL NORMAL 55 15.99 NORMAL 0.84 0.67 1.25 228 NORMAL
63 KUMUDHA 42 F 6 NO 21.00 NORMAL 128/90UNCONTROLLED 2.87 1.31 NO 3.88 5.20 3.60 0.90 1.20 0.90 1.40 101.00 NORMAL NORMAL 57 14.01 NORMAL 0.82 0.92 0.78 268 ABNORMAL
64 CHANDRAMOHAN 54 M 6 NO 25.28 OBESE 120/70 CONTROLLED 2.56 0.95 NO 2.54 4.30 3.03 0.90 1.30 1.10 1.20 258.00 ABNORMAL MILD 56 10.47 NORMAL 1.00 0.84 1.18 174 NORMAL
65 KUMAR 46 M 2 NO 27.51 OBESE 130/100UNCONTROLLED 3.30 1.23 NO 3.60 4.80 2.70 1.10 1.60 1.10 1.30 260.00 ABNORMALMODERATE 60 15.40 NORMAL 0.76 0.64 1.20 0.72 NORMAL
66 CHANDRA 50 F 3 YES 28.30 OBESE 142/96UNCONTROLLED 2.20 1.00 NO 3.77 5.10 2.90 0.90 1.40 0.90 1.30 163.00 ABNORMAL MILD 75 17.18 NORMAL 0.81 1.06 0.77 268 ABNORMAL
67 JAYARAMAN 50 M 3 NO 26.57 OBESE 158/100UNCONTROLLED 2.20 0.78 NO 3.77 5.11 2.86 0.91 1.43 0.91 1.30 196.00 NORMAL NORMAL 75 1.00 NORMAL 1.17 0.98 1.08 242 ABNORMAL
68 SARASWATHY 56 F 3 NO 32.05 OBESE 160/90UNCONTROLLED 2.77 1.13 NO 3.55 4.90 2.60 0.90 1.00 1.40 1.60 361.00 ABNORMAL SEVERE 76 13.44 NORMAL 0.58 0.99 0.59 288 ABNORMAL
69 PREMAVATHY 63 F 6 NO 29.90 OBESE 150/90UNCONTROLLED 2.80 1.35 NO 3.90 4.60 3.40 0.80 1.10 1.00 1.50 138.00 NORMAL NORMAL 55 14.75 NORMAL 0.86 1.01 0.85 288 ABNORMAL
70 KUMUDHA 37 F 4 NO 24.65 OVERWEIGHT 138/94UNCONTROLLED 3.08 1.26 NO 3.68 4.20 2.60 1.00 1.30 1.30 1.50 167.00 ABNORMAL MILD 71 15.57 NORMAL 0.47 0.84 0.92 270 ABNORMAL
71 RAMESH 50 M 6 YES 29.29 OBESE 150/90UNCONTROLLED 3.04 1.19 NO 4.12 5.50 3.20 9.00 1.30 1.10 1.60 213.00 NORMAL NORMAL 71 16.26 NORMAL 0.86 1.02 0.82 270 ABNORMAL
72 AMUDHA 38 F 2 NO 22.50 NORMAL 120/80 CONTROLLED 2.75 1.19 NO 2.80 4.40 3.10 0.90 1.10 1.90 1.30 128.00 NORMAL NORMAL 56 15.18 NORMAL 0.91 0.82 1.11 180 NORMAL
73 MAARISAMY 38 M 2 NO 29.07 OBESE 150/80UNCONTROLLED 2.92 1.01 NO 2.50 4.20 2.60 0.90 1.50 1.20 1.70 147.00 NORMAL NORMAL 67 17.33 NORMAL 0.88 0.73 1.20 216 NORMAL
74 SHANKAR 47 M 0.1 YES 21.15 NORMAL 170/96UNCONTROLLED 3.05 1.09 NO 3.88 4.70 2.80 0.90 1.40 1.00 1.50 279.00 ABNORMALMODERATE 73 13.18 NORMAL 0.86 0.73 1.18 174 NORMAL
75 VIJAYA 50 F 0.6 NO 24.12 OVERWEIGHT190/100UNCONTROLLED 3.42 1.50 NO 3.74 4.70 3.40 1.10 1.30 1.10 1.40 187.00 ABNORMALMODERATE 60 14.65 NORMAL 1.01 0.75 1.36 222 NORMAL
76 ESWARI 60 F 0.1 NO 26.48 OBESE 160/100UNCONTROLLED 2.32 0.99 NO 3.18 5.80 4.20 1.00 1.20 0.80 1.30 203.00 ABNORMALMODERATE 60 15.42 NORMAL 0.84 0.94 0.80 288 ABNORMAL
77 MAARIMUTHU 56 M 2 YES 24.61 OVERWEIGHT150/100UNCONTROLLED 2.89 1.06 NO 3.34 5.10 3.90 1.10 1.40 0.80 1.40 176.00 NORMAL NORMAL 64 12.98 NORMAL 0.74 0.95 0.78 270 ABNORMAL
78 KABALI 62 M 3 YES 24.80 OVERWEIGHT 136/98UNCONTROLLED 3.04 1.08 NO 4.12 5.00 3.80 1.10 1.40 0.90 1.40 182.00 NORMAL NORMAL 60 13.00 NORMAL 0.80 0.84 0.95 264 ABNORMAL
79 THANGARAJ 64 M 12 NO 21.87 NORMAL 150/100UNCONTROLLED 3.11 1.21 NO 3.10 5.10 2.80 1.50 2.10 1.50 1.70 332.00 ABNORMAL SEVERE 69 15.91 NORMAL 1.25 1.33 0.64 290 ABNORMAL
80 PRAKASH 56 M 1 NO 34.57 OBESE 156/88UNCONTROLLED 3.58 1.33 NO 4.42 5.30 3.00 1.10 1.60 1.20 1.60 242.00 ABNORMAL MILD 73 17.66 NORMAL 0.89 0.97 0.82 270 ABNORMAL
81 MAHENDRAN 41 M 3 NO 22.22 NORMAL 120/80 CONTROLLED 2.90 1.29 NO 3.14 5.06 3.29 0.98 1.23 0.98 1.28 194.00 NORMAL NORMAL 60 15.85 NORMAL 0.88 0.59 1.48 186 NORMAL
82 SUNDARAM 49 M 1 YES 28.05 OBESE 120/80 CONTROLLED 3.30 1.24 NO 2.70 4.50 2.70 1.20 1.80 1.00 1.30 175.00 NORMAL NORMAL 71 15.29 NORMAL 0.78 1.09 0.72 264 ABNORMAL
83 SARANYA 43 F 12 NO 27.83 OBESE 120/80 CONTROLLED 3.27 1.38 NO 3.75 4.50 3.10 1.70 2.20 1.30 1.60 276.00 ABNORMAL SEVERE 58 18.77 NORMAL 0.97 0.81 2.20 114 ABNORMAL
84 MAHALAKSHMI 31 F 0.3 NO 22.22 NORMAL 130/80 CONTROLLED 2.37 1.05 NO 2.50 4.20 2.50 0.80 1.00 0.90 1.30 110.00 NORMAL NORMAL 73 12.21 NORMAL 0.80 0.73 1.10 96 NORMAL
85 RADHAKRISHNAN 63 M 14 NO 34.29 OBESE 140/90UNCONTROLLED 3.30 1.26 NO 2.80 5.30 3.60 1.10 1.70 1.10 1.40 228.00 ABNORMAL MILD 61 19.50 NORMAL 0.60 1.06 0.57 292 ABNORMAL
86 PANKAJAM 56 F 2 NO 25.91 OBESE 150/90UNCONTROLLED 2.75 1.27 NO 2.96 4.50 3.00 1.10 1.40 0.90 1.10 153.00 NORMAL NORMAL 61 16.70 NORMAL 0.90 0.82 1.10 120 NORMAL
87 MANGAYAKANNI 45 F 1 NO 20.23 NORMAL 140/90UNCONTROLLED 3.54 1.49 NO 2.60 5.10 2.90 1.20 1.60 1.10 1.40 227.00 ABNORMAL SEVERE 73 16.30 NORMAL 0.60 0.84 0.81 272 ABNORMAL
88 GABRIEL 37 M 4 NO 23.79 OVERWEIGHT 180/98UNCONTROLLED 3.00 1.11 NO 3.20 4.60 3.00 1.00 1.40 1.00 1.40 159.00 NORMAL NORMAL 70 17.00 NORMAL 0.85 0.78 1.10 78 NORMAL
89 MANGALADEVI 55 F 8 NO 29.21 OBESE 180/100UNCONTROLLED 3.00 1.37 NO 3.65 4.50 2.70 1.10 1.40 1.00 1.30 164.00 ABNORMAL MILD 69 15.17 NORMAL 0.47 0.93 0.54 294 ABNORMAL
90 KARUNAKARAN 38 F 2 NO 20.93 NORMAL 154/90UNCONTROLLED 2.84 1.21 NO 3.00 4.20 2.60 1.30 1.00 1.10 1.50 178.00 ABNORMAL MILD 70 17.00 NORMAL 0.61 0.75 0.80 272 ABNORMAL
91 SELVI 59 F 0.6 NO 21.91 NORMAL 120/80 CONTROLLED 2.41 1.10 NO 2.49 4.30 2.60 0.80 1.20 1.00 1.50 123.00 NORMAL NORMAL 70 17.63 NORMAL 1.09 0.92 1.18 180 NORMAL
92 RAMESHBABU 45 M 7 NO 26.57 OBESE 140/90UNCONTROLLED 2.90 1.03 NO 3.14 5.10 3.30 1.00 1.20 1.00 1.30 188.00 NORMAL NORMAL 64 16.93 NORMAL 1.01 0.76 1.33 168 NORMAL
93 SAKTHI 60 F 0.1 NO 26.48 OBESE 160/100UNCONTROLLED 2.32 0.99 NO 3.18 5.80 4.20 1.00 1.20 0.80 1.30 203.00 ABNORMALMODERATE 60 15.42 NORMAL 0.84 0.94 0.80 288 ABNORMAL
94 JAMEEL 63 M 12 NO 29.13 OBESE 140/96UNCONTROLLED 3.31 1.38 NO 2.70 4.90 3.30 1.20 1.60 0.80 1.10 176.00 NORMAL NORMAL 61 17.70 NORMAL 0.71 0.91 0.78 290 ABNORMAL
95 VENKATESAN 55 M 1 NO 23.22 OVERWEIGHT 140/90UNCONTROLLED 2.78 1.01 NO 3.30 4.10 2.90 1.10 1.20 0.90 1.20 132.00 NORMAL NORMAL 61 11.26 NORMAL 0.71 0.92 0.78 256 ABNORMAL
96 RAM KUMAR 46 M 2 YES 26.77 OBESE 158/92UNCONTROLLED 3.33 1.24 NO 3.60 4.80 2.70 1.10 1.60 1.10 1.40 194.00 NORMAL NORMAL 76 15.40 NORMAL 0.76 0.64 1.20 72 NORMAL
97 DEVI 40 F 1 NO 25.55 OBESE 140/84UNCONTROLLED 3.10 1.50 NO 2.90 4.60 2.60 0.80 1.50 0.80 1.10 118.00 NORMAL NORMAL 73 17.00 NORMAL 0.90 0.97 0.79 264 ABNORMAL
98 SELVAKUMAR 46 M 2 NO 27.51 OBESE 130/100UNCONTROLLED 3.30 1.23 NO 3.60 4.80 2.70 1.10 1.60 1.10 1.30 260.00 ABNORMALMODERATE 60 15.40 NORMAL 0.76 0.64 1.20 0.72 NORMAL
99 RUKMANI 43 F 5 NO 29.77 OBESE 130/80 CONTROLLED 3.41 1.42 NO 3.00 5.00 3.10 1.10 1.50 0.90 1.20 170.00 ABNORMAL MILD 68 18.00 NORMAL 1.18 0.80 1.47 138 NORMAL
100 RAJASEKAR 55 M 5 NO 23.53 OVERWEIGHT150/112UNCONTROLLED 3.25 1.12 NO 3.48 4.60 3.50 1.10 0.83 0.90 1.30 159.00 NORMAL NORMAL 70 15.34 NORMAL 0.96 0.71 1.40 144 NORMAL
